Sight Sciences is an ophthalmic medical device company that develops and commercializes surgical and nonsurgical technologies for the treatment of eye diseases. Founded in 2010 by brothers Paul and David Badawi and headquartered in Menlo Park, California, the company operates through two segments: Surgical Glaucoma (anchored by the OMNI Surgical System, a handheld device used by ophthalmic surgeons to perform canaloplasty and trabeculotomy in patients with primary open-angle glaucoma) and Dry Eye (anchored by the TearCare System, a wearable, software-controlled treatment for meibomian gland dysfunction-related dry eye). Sight Sciences went public on the Nasdaq Global Market in July 2021 under the ticker SGHT, with a $276 million IPO at a valuation above $1 billion.
Sight Sciences is publicly traded
IPO'd on July 15, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under SGHT.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2010
Employees
201–500
Total Funding
$123M
4 rounds
Total raised $123M across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series D
Date
August 2020
Amount
$65M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| August 2020 | Series D | $65M | — | D1 Capital Partners |
| November 13, 2018 | Series C | $30M | — | D1 Capital Partners |
| 2016 | Series B | $18M | — | Not disclosed |
Paul Badawi
Co-Founder & Chief Executive Officer
David Badawi
Co-Founder
Alison (Ali) Bauerlein
Chief Operating Officer
James (Jim) Rodberg
Chief Financial Officer
Jeremy Hayden
General Counsel
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Glaukos
Public ophthalmic medical device company and the dominant player in MIGS, marketing the iStent family of trabecular micro-bypass stents for glaucoma; the most direct competitor to Sight Sciences' OMNI Surgical System.
Alcon
Global eye-care company that strengthened its MIGS position by acquiring Ivantis (maker of the Hydrus Microstent) for $475M, competing directly with Sight Sciences in surgical glaucoma.
Johnson & Johnson Vision
Ophthalmic division of J&J that markets the SION surgical instrument and other glaucoma devices, competing in the MIGS and broader surgical ophthalmology space.
Nova Eye Medical
Australian ophthalmic device company offering the iTrack microcatheter for canaloplasty, a direct competitor to OMNI in MIGS canaloplasty.
Bausch + Lomb
Global eye-health company with a portfolio of dry-eye treatments (e.g., Miebo) competing with Sight Sciences' TearCare System in the dry eye disease market.
iSTAR Medical
Belgian ophthalmic device company developing the MINIject supraciliary glaucoma implant, an emerging MIGS competitor.
Yes, Sight Sciences is publicly traded under the ticker symbol SGHT on the NASDAQ. The company went public in July 15, 2021.
Sight Sciences trades under the ticker symbol SGHT on the NASDAQ. It began trading in July 15, 2021.
Sight Sciences (SGHT on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker SGHT to place an order.
Sight Sciences went public in July 15, 2021 via ipo. Sight Sciences completed its initial public offering on the Nasdaq Global Market on July 15, 2021, pricing 11.5 million shares at $24.00 per share for gross proceeds of $276 million and an implied valuation of approximately $1 billion. The company trades under the ticker SGHT.
Sight Sciences raised $123M across 4 disclosed funding rounds prior to its public listing.
Sight Sciences was co-founded by Paul Badawi, and David Badawi in 2010.
Sight Sciences is headquartered in Menlo Park, CA, USA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.